[go: up one dir, main page]

MA50065A - Dérivés de composés de spiro[3h-indole-3,2´-pyrrolidine]-2(1h)-one et dérivés utilisés comme inhibiteurs de mdm2-p53 - Google Patents

Dérivés de composés de spiro[3h-indole-3,2´-pyrrolidine]-2(1h)-one et dérivés utilisés comme inhibiteurs de mdm2-p53

Info

Publication number
MA50065A
MA50065A MA050065A MA50065A MA50065A MA 50065 A MA50065 A MA 50065A MA 050065 A MA050065 A MA 050065A MA 50065 A MA50065 A MA 50065A MA 50065 A MA50065 A MA 50065A
Authority
MA
Morocco
Prior art keywords
mdm2
inhibitors
compounds
spiro
pyrrolidine
Prior art date
Application number
MA050065A
Other languages
English (en)
Other versions
MA50065B1 (fr
Inventor
Joachim Broeker
Annika Gille
Stefan Goepper
Andreas Gollner
Manuel Henry
Guenther Huchler
Nina Kerres
Christiane Kofink
Juergen Ramharter
Harald Weinstabl
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA50065A publication Critical patent/MA50065A/fr
Publication of MA50065B1 publication Critical patent/MA50065B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne des composés de formule (i) dans laquelle les groupes r1 à r4, r7, a, d, e, f, v, w, x, y, n, r et q sont définis dans la revendication 1, leur utilisation à titre d'inhibiteurs de l'interaction mdm2-p53, des compositions pharmaceutiques les contenant, leur utilisation à titre de médicaments, notamment à titre d'agents destinés à traiter et/ou à prévenir les maladies oncologiques, et les intermédiaires formés au cours de leur synthèse.
MA50065A 2015-10-09 2016-10-07 Dérivés de composés de spiro[3h-indole-3,2´-pyrrolidine]-2(1h)-one et dérivés utilisés comme inhibiteurs de mdm2-p53 MA50065B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15189210 2015-10-09
PCT/EP2016/074008 WO2017060431A1 (fr) 2015-10-09 2016-10-07 Composés de spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one et leurs dérivés à titre d'inhibiteurs de mdm2-p53

Publications (2)

Publication Number Publication Date
MA50065A true MA50065A (fr) 2018-08-15
MA50065B1 MA50065B1 (fr) 2021-06-30

Family

ID=54292702

Family Applications (1)

Application Number Title Priority Date Filing Date
MA50065A MA50065B1 (fr) 2015-10-09 2016-10-07 Dérivés de composés de spiro[3h-indole-3,2´-pyrrolidine]-2(1h)-one et dérivés utilisés comme inhibiteurs de mdm2-p53

Country Status (32)

Country Link
US (4) US10144739B2 (fr)
EP (1) EP3359542B1 (fr)
JP (1) JP6602470B2 (fr)
KR (2) KR102722493B1 (fr)
CN (5) CN119569739A (fr)
AR (1) AR106314A1 (fr)
AU (1) AU2016333721B2 (fr)
BR (1) BR112018007155B1 (fr)
CA (1) CA3000063A1 (fr)
CL (1) CL2018000666A1 (fr)
CO (1) CO2018003565A2 (fr)
CY (1) CY1124284T1 (fr)
DK (1) DK3359542T3 (fr)
EA (1) EA036013B1 (fr)
ES (1) ES2873895T3 (fr)
HR (1) HRP20210960T1 (fr)
HU (1) HUE054985T2 (fr)
IL (1) IL258073B (fr)
LT (1) LT3359542T (fr)
MA (1) MA50065B1 (fr)
MX (1) MX377009B (fr)
MY (1) MY199688A (fr)
PE (1) PE20181205A1 (fr)
PH (1) PH12018500763A1 (fr)
PL (1) PL3359542T3 (fr)
PT (1) PT3359542T (fr)
RS (1) RS61936B1 (fr)
SA (1) SA518391307B1 (fr)
SI (1) SI3359542T1 (fr)
TW (1) TWI737635B (fr)
UA (1) UA123905C2 (fr)
WO (1) WO2017060431A1 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3129380B1 (fr) 2014-04-11 2018-11-28 Boehringer Ingelheim International Gmbh Dérivés spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one et leur utilisation en tant qu'inhibiteurs de mdm2-p53
EP3164401B1 (fr) 2014-07-03 2018-12-26 Boehringer Ingelheim International GmbH Nouvelles spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one composés et leur dérivés comme inhibiteurs de mdm2-p53
DK3183254T3 (da) 2014-08-21 2019-08-19 Boehringer Ingelheim Int Nye spiro[3h-indol-3,2 ?-pyrrolidin]-2(1h)-one forbindelser og derivater som mdm2-p53 inhibitorer
WO2017060431A1 (fr) 2015-10-09 2017-04-13 Boehringer Ingelheim International Gmbh Composés de spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one et leurs dérivés à titre d'inhibiteurs de mdm2-p53
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
CN110505884B (zh) 2017-04-05 2022-08-12 勃林格殷格翰国际有限公司 抗癌组合疗法
CN112041320B (zh) * 2017-12-29 2023-05-23 甘李药业股份有限公司 一种可用作肿瘤抑制剂的化合物及其制备方法与应用
EP3511334A1 (fr) * 2018-01-16 2019-07-17 Adamed sp. z o.o. Composés de 1,2,3',5'-tetrahydro-2'h-spiro[indole-3,1'-pyrrolo[3,4-c]pyrrole] -2,3'-dione comme agents thérapeutiques activant le tp53
WO2020018611A1 (fr) * 2018-07-18 2020-01-23 Dana-Farber Cancer Institute, Inc. Compositions et méthodes d'identification, d'évaluation, de prévention et de traitement d'un sarcome d'ewing à l'aide de biomarqueurs et de modulateurs de la dépendance de tp53
US10590147B1 (en) 2019-09-10 2020-03-17 King Saud University Spirooxindole-pyrrolothiazole heterocyclic hybrids
US11285159B2 (en) * 2019-11-05 2022-03-29 Abbvie Inc. Dosing regimens for use in treating myelofibrosis and MPN-related disorders with navitoclax
PE20240493A1 (es) 2020-06-02 2024-03-15 Boehringer Ingelheim Int 2-amino-3-cianotiofenos anulados y derivados para el tratamiento del cancer
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
CN112047951A (zh) * 2020-10-16 2020-12-08 吉林大学 手性螺[吡咯-2，2’-呋喃]化合物及其制备方法
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
MX2024001832A (es) 2021-08-09 2024-02-28 Boehringer Ingelheim Int Nueva composicion farmaceutica oral para terapias contra el cancer.
US20250313553A1 (en) 2021-12-01 2025-10-09 Boehringer Ingelheim Int'l GmbH Corp. Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
TW202340208A (zh) 2021-12-01 2023-10-16 德商百靈佳殷格翰國際股份有限公司 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
WO2023099624A1 (fr) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh 2-amino-3-cyano thiophènes annelés et leurs dérivés pour le traitement du cancer
WO2023099620A1 (fr) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Composés de dégradation de kras comprenant des 2-amino-3-cyano thiophènes annelés
US20250129095A1 (en) 2021-12-01 2025-04-24 Boehringer Ingelheim Int'l GmbH Corp. Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
TW202440585A (zh) 2022-12-22 2024-10-16 德商百靈佳殷格翰國際股份有限公司 MDM2-p53抑制劑之晶型及醫藥組合物
EP4638416A1 (fr) 2022-12-23 2025-10-29 Boehringer Ingelheim International GmbH Nouveau procédé de fabrication d'antagonistes de mdm2-p53
WO2024238404A2 (fr) * 2023-05-12 2024-11-21 Pmv Pharmaceuticals, Inc. Polythérapie pour le traitement du cancer
AR132802A1 (es) 2023-05-30 2025-07-30 Boehringer Ingelheim Int 2-amino-3-cianotiofenos con anillos espirocíclicos y derivados para el tratamiento del cáncer
WO2024246114A1 (fr) 2023-05-31 2024-12-05 Boehringer Ingelheim International Gmbh Survivine en tant que biomarqueur pour prédire la réactivité d'un traitement du cancer

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3361759A (en) 1963-10-07 1968-01-02 Upjohn Co 3-(2-pyrrolidinyl)-indoles and method of preparation
US4219560A (en) 1978-04-17 1980-08-26 Sandoz, Inc. Piperidine and pyrrolidine alcohols
US5574044A (en) 1994-10-27 1996-11-12 Merck & Co., Inc. Muscarine antagonists
WO1999012904A1 (fr) 1997-09-08 1999-03-18 Arqule, Inc. Composes de spiro[pyrrolidine-2,3'-oxindole] et procedes d'utilisation
EP1180513A4 (fr) 1999-04-28 2002-07-10 Takeda Chemical Industries Ltd Composes d'amides cycliques, leurs procedes de preparation et d'utilisation
JP2006234861A (ja) 2005-02-22 2006-09-07 Fujinon Sano Kk 光学ガラスの製造方法，偏光変換素子の製造方法及び偏光変換素子
MX2007010272A (es) 2005-02-22 2008-03-12 Univ Michigan Inhibidores de moleculas pequenas de mdm2 y usos de los mismos.
EP1858902A1 (fr) 2005-02-24 2007-11-28 Pfizer Products Incorporated Derives heteroaromatiques bicycliques utilises comme agents anticancereux
US20070213341A1 (en) 2006-03-13 2007-09-13 Li Chen Spiroindolinone derivatives
JP2009530236A (ja) 2006-03-13 2009-08-27 エフ．ホフマン−ラ ロシュ アーゲー スピロインドリノン誘導体
AU2007269836A1 (en) 2006-06-30 2008-01-10 Albany Molecular Research, Inc. Substituted piperidines that increase P53 activity and the uses thereof
CN101528223B (zh) 2006-08-30 2013-05-01 密执安州立大学董事会 Mdm2的新型小分子抑制剂和其用途
WO2008119741A2 (fr) 2007-03-29 2008-10-09 Novartis Ag 3-imidazolyl-indoles pour le traitement de maladies prolifératives
US7553833B2 (en) 2007-05-17 2009-06-30 Hoffmann-La Roche Inc. 3,3-spiroindolinone derivatives
US7834179B2 (en) 2007-05-23 2010-11-16 Hoffmann-La Roche Inc. Spiroindolinone derivatives
US7977358B2 (en) 2007-07-26 2011-07-12 Hoffmann-La Roche Inc. Pyrazol derivatives
US8134001B2 (en) 2007-12-14 2012-03-13 Hoffmann-La Roche Inc. Spiroindolinone derivatives
US7776875B2 (en) 2007-12-19 2010-08-17 Hoffman-La Roche Inc. Spiroindolinone derivatives
AR073578A1 (es) * 2008-09-15 2010-11-17 Priaxon Ag Pirrolidin-2-onas
US20100190814A1 (en) 2009-01-26 2010-07-29 Li Chen Spiroindolinone derivative prodrugs
US8076482B2 (en) 2009-04-23 2011-12-13 Hoffmann-La Roche Inc. 3,3′-spiroindolinone derivatives
PH12012500870A1 (en) 2009-11-12 2012-11-26 Univ Michigan Regents Spiro-oxindole mdm2 antagonists
US8088815B2 (en) 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
US8288431B2 (en) 2010-02-17 2012-10-16 Hoffmann-La Roche Inc. Substituted spiroindolinones
US8217044B2 (en) 2010-04-28 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone pyrrolidines
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
US20120046306A1 (en) 2010-08-18 2012-02-23 David Joseph Bartkovitz Substituted Heteroaryl Spiropyrrolidine MDM2 Antagonists
US20120071499A1 (en) 2010-09-20 2012-03-22 Xin-Jie Chu Substituted Spiro[3H-Indole-3,6'(5'H)-[1H]Pyrrolo[1,2c]Imidazole-1',2(1H,2'H)-diones
PE20140408A1 (es) 2010-11-12 2014-04-10 Univ Michigan Derivados espiro-oxindol como antagonistas de mdm2
US20130053410A1 (en) 2011-03-03 2013-02-28 David Joseph Bartkovitz Substituted heteroaryl 2',3',7',7a'-tetrahydrospiro[pyrrole-3,6'-pyrrolo[1,2-c]imidazole]-1',2(1h,5'h)-dione
CA2829188C (fr) 2011-03-10 2016-10-18 Daiichi Sankyo Company, Limited Derive de dispiropyrrolidine
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
EP2707372B1 (fr) 2011-05-11 2016-12-21 The Regents Of The University Of Michigan Agonistes de mdm2 consistant en spiro-oxindoles
CN102443004A (zh) * 2011-11-01 2012-05-09 南京工业大学 有机发光材料6,7,14,15-四氢-5,13-二取代苯并[1,2-c:4,5-c’]二吖啶类化合物、合成方法及应用
CN103910746B (zh) * 2014-02-28 2016-08-03 中山大学 一类海洋真菌来源的Berkeleyones化合物及其制备方法和应用
EP3129380B1 (fr) 2014-04-11 2018-11-28 Boehringer Ingelheim International Gmbh Dérivés spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one et leur utilisation en tant qu'inhibiteurs de mdm2-p53
KR102389552B1 (ko) 2014-04-17 2022-04-22 더 리젠츠 오브 더 유니버시티 오브 미시간 Mdm2 저해제 및 이 저해제를 사용하는 치료 방법
EP3164401B1 (fr) 2014-07-03 2018-12-26 Boehringer Ingelheim International GmbH Nouvelles spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one composés et leur dérivés comme inhibiteurs de mdm2-p53
WO2016028391A2 (fr) 2014-08-18 2016-02-25 Hudson Biopharma Inc. Spiropyrrolidines utiles en tant qu'inhibiteurs de mdm2
DK3183254T3 (da) 2014-08-21 2019-08-19 Boehringer Ingelheim Int Nye spiro[3h-indol-3,2 ?-pyrrolidin]-2(1h)-one forbindelser og derivater som mdm2-p53 inhibitorer
NO2721710T3 (fr) 2014-08-21 2018-03-31
PL3341355T3 (pl) 2015-10-09 2021-03-08 Northwestern University Kwas (S)-3-amino-4-(difluorometylenylo)cyklopent-1-eno-1-karboksylowy i związki pokrewne jako dezaktywatory aminotransferazy GABA do leczenia padaczki, uzależnienia oraz raka wątrobowokomórkowego
KR20180083323A (ko) 2015-10-09 2018-07-20 애브비 에스.에이.알.엘. N-설포닐화 피라졸로[3,4-b]피리딘-6-카복스아미드 및 사용 방법
WO2017060431A1 (fr) * 2015-10-09 2017-04-13 Boehringer Ingelheim International Gmbh Composés de spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one et leurs dérivés à titre d'inhibiteurs de mdm2-p53
JP2018017594A (ja) * 2016-07-27 2018-02-01 セイコーエプソン株式会社 動力伝達装置、ロボットおよびプリンター
CN106967049B (zh) 2017-03-22 2018-06-26 杭州师范大学 一种白藜芦醇系列荧光标记分子及其合成方法

Also Published As

Publication number Publication date
JP2018533558A (ja) 2018-11-15
CY1124284T1 (el) 2022-07-22
PT3359542T (pt) 2021-05-25
US10882866B1 (en) 2021-01-05
SI3359542T1 (sl) 2021-08-31
MX377009B (es) 2025-03-07
TW201722961A (zh) 2017-07-01
CN113214270A (zh) 2021-08-06
MY199688A (en) 2023-11-17
LT3359542T (lt) 2021-05-25
KR20240158360A (ko) 2024-11-04
IL258073B (en) 2021-05-31
EA036013B1 (ru) 2020-09-14
MA50065B1 (fr) 2021-06-30
AR106314A1 (es) 2018-01-03
TWI737635B (zh) 2021-09-01
KR20180058832A (ko) 2018-06-01
CL2018000666A1 (es) 2018-08-10
CN119569741A (zh) 2025-03-07
WO2017060431A1 (fr) 2017-04-13
SA518391307B1 (ar) 2021-11-25
AU2016333721A1 (en) 2018-03-22
MX2018004207A (es) 2018-07-06
AU2016333721B2 (en) 2020-07-16
NZ740312A (en) 2024-11-29
BR112018007155B1 (pt) 2022-12-13
IL258073A (en) 2018-05-31
CN119569739A (zh) 2025-03-07
USRE50594E1 (en) 2025-09-23
JP6602470B2 (ja) 2019-11-06
US20170174695A1 (en) 2017-06-22
HRP20210960T1 (hr) 2021-09-03
EA201890888A1 (ru) 2018-10-31
CN108137590B (zh) 2021-04-09
EP3359542B1 (fr) 2021-03-17
PH12018500763A1 (en) 2018-10-29
US10144739B2 (en) 2018-12-04
ES2873895T3 (es) 2021-11-04
CN108137590A (zh) 2018-06-08
PE20181205A1 (es) 2018-07-23
DK3359542T3 (da) 2021-05-31
KR102722493B1 (ko) 2024-10-29
RS61936B1 (sr) 2021-07-30
US20180273541A1 (en) 2018-09-27
US10717742B2 (en) 2020-07-21
EP3359542A1 (fr) 2018-08-15
CA3000063A1 (fr) 2017-04-13
CN119569740A (zh) 2025-03-07
HK1252365A1 (en) 2019-05-24
HUE054985T2 (hu) 2021-11-29
BR112018007155A2 (pt) 2018-11-06
UA123905C2 (uk) 2021-06-23
PL3359542T3 (pl) 2021-09-20
CO2018003565A2 (es) 2018-07-10

Similar Documents

Publication Publication Date Title
MA50065B1 (fr) Dérivés de composés de spiro[3h-indole-3,2´-pyrrolidine]-2(1h)-one et dérivés utilisés comme inhibiteurs de mdm2-p53
ZA202500997B (en) Benzoxazepin oxazolidinone compounds and methods of use
MA42230A (fr) Dérivés bicycliques, leur procédé de préparation, et compositions pharmaceutiques les contenant
AR077935A1 (es) Derivados de 3-amino-5 fenil-5,6-dihidro-2h-(1,4)oxazina
BR112017002942A2 (pt) compostos e derivados de espiro[3h-indol-3,2´-pirrolidin]2(1h)-ona como inibidores de mdm2-p53
EA200500342A1 (ru) Гетероциклические замещённые пиперазины для лечения шизофрении
MA43639B1 (fr) Nouveaux dérivés d'ammonium, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant
MA31419B1 (fr) Derives de pyridine
EA200701036A1 (ru) Лактамные соединения и их применение в качестве фармацевтических препаратов
MA42239B1 (fr) Nouveaux dérivés d'hydroxyester, leur procédé de préparation et compositions pharmaceutiques les contenant
MA38380A1 (fr) Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr)
AR029301A1 (es) Compuestos derivados de biarilo, metodos para su preparacion composiciones que los contienen, su uso como agonistas en receptores beta-adreno-receptores atipicos
CL2010001486A1 (es) Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de jak; composicion farmaceutica; kit farmaceutico; su uso en el tratamiento de enfermedades tales como cancer, diabetes, enfermedad de alzheimer, enfermedad hepatica, trastornos del snc, entre otras.
EA201391670A1 (ru) 1,3-оксазины в качестве ингибиторов bace1 и/или bace2
AR066111A1 (es) Compuesto triciclico de imidazol, su uso para preparar un medicamento, composicion farmaceutica que lo comprende y compuestos intermediarios en la sintesis de dicho compuesto
AR079541A1 (es) Compuestos sustituidos de n-(1h-indazol-4-il) imidazo (1,2-a) piridin-3-carboxamida como inhibidores de cfms
MA46229B1 (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
CL2007002899A1 (es) Compuestos derivados de azaciclilaminas n-sustituidas, inhibidores del receptor de histamina 3; proceso de preparacion; composicion farmaceutica que comprende los compuestos, y usopara el tratamiento de trastornos cognitivos, esquizofre nia y enfermedad de alzheimer entre otros.
MA39707A (fr) Dérivés de 1,2-dihydro-3h-pyrrolo [1,2-c]imidazol-3-one et leur utilisation comme agents antibactériens
MA40875A (fr) 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux
AR072809A1 (es) Compuesto de (3- piridinilcarbonil)-4-(fenilsulfonilpiperazina ), su uso para la elaboracion de unmedicamento para el tratamiento del dolor y composicion farmaceutica que lo comprende
AR049711A1 (es) Compuestos heterociclicos condensados como inhibidores de la aldosterona sintasa; composiciones farmaceuticas que los contienen y su uso en la preparacion de un medicamento para el tratamiento o prevencion de enfermedades relacionadas con el hiperaldosterismo y por una liberacion excesiva de cortiso
EA200801184A1 (ru) Производные пипередин-4-ил-пиридазин-3-иламина как быстро диссоциирующие антагонисты рецептора дофамина 2
PE20232046A1 (es) N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)-quinolin-4-carboxamidas
AR051686A1 (es) Derivados de piridotienopirimidina; composiciones farmaceuticas que los contienen y su empleo en la fabricacion de un medicamento para el tratamiento de enfermedaes mediadas por inhibicion de pde4.